Package Leaflet: Information for the Patient
Sitagliptin/Metformin Dr. Reddys 50 mg/850 mg film-coated tablets EFG
Sitagliptin/Metformin Dr. Reddys 50 mg/1000 mg film-coated tablets EFG
sitagliptin/metformin hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
This medicine contains two different medicines called sitagliptin and metformin.
They work together to control the levels of sugar in the blood in adult patients with a form of diabetes called “type 2 diabetes mellitus”. This medicine helps to increase the amounts of insulin produced after a meal and reduces the amount of sugar produced by your body.
Together with diet and exercise, this medicine helps to lower your blood sugar levels. This medicine can be used alone or with certain other medicines for diabetes (insulin, sulfonylureas, or glitazones).
What is type 2 diabetes?
Type 2 diabetes is a condition in which your body does not produce enough insulin and the insulin that your body produces does not work as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, such as diseases that affect the heart, diseases that affect the kidneys, blindness, and amputations.
Do not take Sitagliptin/Metformin Dr. Reddys:
Do not take sitagliptin/metformin if you are affected by any of the above conditions and consult your doctor about other ways to control your diabetes. If you are not sure, consult your doctor, pharmacist, or nurse before taking sitagliptin/metformin.
Warnings and precautions
There have been reports of pancreatitis (inflammation of the pancreas) in patients treated with sitagliptin/metformin (see section 4).
If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking sitagliptin/metformin.
Risk of lactic acidosis
Sitagliptin/metformin may cause a very rare but very serious side effect called lactic acidosis, especially if your kidneys are not working properly. The risk of developing lactic acidosis is also increased by uncontrolled diabetes, serious infections, prolonged fasting, or alcohol intake, dehydration (see more information below), liver problems, and any medical condition in which a part of your body has a reduced supply of oxygen (such as acute and severe heart diseases).
If any of the above applies to you, consult your doctor for further instructions.
Stop taking sitagliptin/metformin for a short period of time if you have a condition that may be associated with dehydration(significant loss of body fluids), such as severe vomiting, diarrhea, fever, heat exposure, or if you drink less fluid than usual. Consult your doctor for further instructions.
Stop taking sitagliptin/metformin and contact a doctor or the nearest hospital immediately if you experience any of the symptoms of lactic acidosis, as this condition can lead to coma.
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and must be treated in a hospital.
Talk to your doctor immediately for further instructions if:
Consult your doctor or pharmacist before starting sitagliptin/metformin:
If you need to undergo major surgery, you should stop taking sitagliptin/metformin during the procedure and for some time after. Your doctor will decide when you should stop taking sitagliptin/metformin and when you can restart it.
If you are not sure if any of the above conditions apply to you, consult your doctor or pharmacist before taking sitagliptin/metformin.
During treatment with sitagliptin/metformin, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person and/or if your kidney function is worsening.
Children and adolescents
Children and adolescents under 18 years of age should not use this medicine. It is not effective in children and adolescents from 10 to 17 years of age. It is not known if this medicine is safe and effective when used in children under 10 years of age.
Other medicines and Sitagliptin/Metformin Dr. Reddys
If you need to be given an injection of a contrast agent containing iodine into your bloodstream, for example, in the context of an X-ray or scan, you should stop taking sitagliptin/metformin before or at the time of the injection. Your doctor will decide when you should stop taking sitagliptin/metformin and when you can restart it.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of sitagliptin/metformin. It is especially important to mention the following:
Taking Sitagliptin/Metformin Dr. Reddys with alcohol
Avoid excessive alcohol intake while taking sitagliptin/metformin, as this may increase the risk of lactic acidosis (see section “Warnings and precautions”).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not take this medicine during pregnancy or while breast-feeding. See section 2, Do not take Sitagliptin/Metformin Dr. Reddys.
Driving and using machines
The effect of this medicine on your ability to drive or use machines is negligible or non-existent. However, there have been reports of dizziness and drowsiness during treatment with sitagliptin, which may affect your ability to drive or use machines.
Taking this medicine with sulfonylureas or insulin may cause hypoglycemia, which may affect your ability to drive or use machines or work without a secure support.
Sitagliptin/Metformin Dr. Reddys contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially “sodium-free”.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
You should continue with the diet recommended by your doctor during treatment with this medicine and be careful to distribute your carbohydrate intake evenly throughout the day.
It is unlikely that treatment with this medicine alone will cause abnormally low blood sugar levels (hypoglycemia). Hypoglycemia may occur when this medicine is taken with a sulfonylurea or insulin, so your doctor may consider it necessary to reduce the dose of your sulfonylurea or insulin.
If you take more Sitagliptin/Metformin Dr. Reddys than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount taken.
If you take more than the prescribed dose of this medicine, contact your doctor immediately. Go to the hospital if you have symptoms of lactic acidosis such as feeling cold or unwell, severe nausea or vomiting, stomach pain, unexplained weight loss, muscle cramps, or rapid breathing (see section “Warnings and precautions”).
If you forget to take Sitagliptin/Metformin Dr. Reddys
If you forget to take a dose, take it as soon as you remember. If you do not remember until the time for your next dose, skip the missed dose and continue with your normal treatment schedule. Do not take a double dose of this medicine.
If you stop taking Sitagliptin/Metformin Dr. Reddys
Keep taking this medicine for as long as your doctor tells you to, so that it can help control your blood sugar levels. Do not stop taking this medicine without first talking to your doctor. If you stop taking sitagliptin/metformin, your blood sugar levels may increase again.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
STOP taking sitagliptin/metformin and go to the doctor immediately if you notice any of the following serious adverse effects:
Sitagliptin/metformin may cause a very rare (may affect up to 1 in 10,000 people) but very serious adverse effect called lactic acidosis (see section "Warnings and Precautions"). If this happens to you, you must stop taking sitagliptin/metformin and contact a doctor or the nearest hospital immediately, as lactic acidosis can lead to coma.
If you have a severe allergic reaction (frequency not known), including skin rash, hives, blisters on the skin/exfoliative dermatitis, and swelling of the face, lips, tongue, and throat that can cause difficulty breathing or swallowing, stop taking this medicine and consult your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and will
change the medicine for the treatment of diabetes.
Some patients who took metformin have experienced the following adverse effects after starting treatment with sitagliptin:
Frequent (may affect up to 1 in 10 people): low blood sugar, nausea, gas, vomiting.
Infrequent (may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, drowsiness.
Some patients have experienced diarrhea, nausea, gas, constipation, stomach pain, or vomiting when starting treatment with the combination of sitagliptin and metformin (frequency classified as frequent).
Some patients have experienced the following adverse effects when taking this medicine with a sulfonylurea such as glimepiride:
Very frequent (may affect more than 1 in 10 people): low blood sugar levels. Frequent: constipation.
Some patients have experienced the following adverse effects while taking this medicine in combination with pioglitazone:
Frequent: swelling of hands or feet.
Some patients have experienced the following adverse effects while taking this medicine in combination with insulin:
Very frequent: low blood sugar levels.
Infrequent: dry mouth, headache.
Some patients have experienced the following adverse effects during clinical trials while taking sitagliptin alone (one of the medicines that contains this medicine or during use after approval of this medicine or sitagliptin alone or with other diabetes medicines:
Frequent: low blood sugar levels, headache, upper respiratory tract infection, nasal congestion or runny nose, and sore throat, arthritis, pain in the arm or leg.
Infrequent: dizziness, constipation, itching.
Rare: reduction in platelet count.
Frequency not known: kidney problems (which may require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister).
Some patients have experienced the following adverse effects after taking metformin alone: Very frequent: nausea, vomiting, diarrhea, stomach pain, and loss of appetite. These symptoms may appear when you start taking metformin and usually disappear.
Frequent: metallic taste, decreased or low vitamin B12 levels in the blood (symptoms may include extreme fatigue, red and sore tongue, tingling, or pale or yellowish skin). Your doctor may schedule some tests to discover the cause of your symptoms because some of these can also be caused by diabetes or other unrelated health problems.
Very rare: reduction in vitamin B12 levels, hepatitis (a liver problem), hives, skin redness (rash), or itching.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
This medicine does not require special storage conditions.
Do not use this medicine after the expiration date that appears on the blister pack and on the container after CAD. The expiration date is the last day of the month indicated.
Medicines should not be thrown away through wastewater or household waste. Deposit the containers and medicines you no longer need in the SIGRE collection point at the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This way, you will help protect the environment.
Composition of Sitagliptin/Metformin Dr. Reddys
Each tablet contains sitagliptin hydrochloride monohydrate equivalent to 50 mg of sitagliptin and 850 mg of metformin hydrochloride.
Each tablet contains sitagliptin hydrochloride monohydrate equivalent to 50 mg of sitagliptin and 1,000 mg of metformin hydrochloride.
Povidone, sodium lauryl sulfate, microcrystalline cellulose, magnesium stearate.
Polyvinyl alcohol (E123), macrogol (E1521), talc (E553b), titanium dioxide (E171).
Only for 50 mg/1,000 mg: red iron oxide (E172) and yellow iron oxide (E172).
Product Appearance and Package Contents
Sitagliptin/Metformin Dr. Reddys 50 mg/850 mg are oval, biconvex, white film-coated tablets with "|" engraved on one face and smooth on the other face.
Approximate tablet dimensions: 20 mm x 10 mm x 6 mm.
Sitagliptin/Metformin Dr. Reddys 50 mg/1,000 mg are oval, biconvex, brown film-coated tablets with a "7" engraved on one face and smooth on the other face.
Approximate tablet dimensions: 21 mm x 10 mm x 7 mm.
OPA/Alu/PVC-Alu blister pack.
Pack sizes of 28, 56, 112, and 196 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Reddy Pharma Iberia, S.A.
Avda. Josep Tarradellas nº 38.
08029 Barcelona,
Spain.
Phone: 93.355.49.16.
Fax: 93.355.49.61.
Manufacturer
betapharm Arzneimittel GmbH.
Kobelweg 95.
86156 Augsburg.
Germany.
or
Rual Laboratories SRL.
313, Splaiul Unirii, Building H, 1st floor, sector 3,
030138 Bucharest.
Romania.
or
Dr Reddy’s Laboratories Romania SRL.
71-73 Nicolae Caramfil, 1st floor, sector 1.
014142 Bucharest.
Romania.
or
Pharmadox Healthcare Ltd.
KW20A Kordin Industrial Park.
Paola PLA 3000 Malta.
This medicine is authorized in the Member States of the European Economic Area under the following names:
Country | Name |
Austria | Sitagliptin/Metformin Reddy 50 mg/850 mg Filmtabletten. Sitagliptin/Metformin Reddy 50 mg/1,000 mg Filmtabletten. |
Czech Republic | Sitagliptin/Metformin Reddy 50 mg/850 mg potahované tablety. Sitagliptin/Metformin Reddy 50 mg/1,000 mg potahované tablety. |
Germany | Sitagliptin/Metformin beta 50 mg/850 mg Filmtabletten. Sitagliptin/Metformin beta 50 mg/1,000 mg Filmtabletten. |
Spain | Sitagliptina/metformina Dr. Reddys 50 mg/850 mg comprimidos recubiertos con película EFG. Sitagliptina/metformina Dr. Reddys 50 mg/1,000 mg comprimidos recubiertos con película EFG. |
Denmark | Sitagliptin/Metformin Reddy 50 mg/850 mg filmovertrukne tabletter. Sitagliptin/Metformin Reddy 50 mg/1,000 mg filmovertrukne tabletter. |
Finland | Sitagliptin/Metformin Reddy 50 mg/850 mg kalvopäällysteiset tabletit. Sitagliptin/Metformin Reddy 50 mg/1,000 mg kalvopäällysteiset tabletit. |
France | SITAGLIPTINE/METFORMINE REDDY PHARMA 50 mg/850 mg, comprimé pelliculé. SITAGLIPTINE/METFORMINE REDDY PHARMA 50 mg/1,000 mg, comprimé pelliculé. |
Italy | Sitagliptin e Metformina Dr. Reddy’s 50 mg/850 mg compresse rivestite con film. Sitagliptin e Metformina Dr. Reddy’s 50 mg/1,000 mg compresse rivestite con film. |
Netherlands | Sitagliptine/Metformine Reddy 50 mg/850 mg filmomhulde tabletten. Sitagliptine/Metformine Reddy 50 mg/1,000 mg filmomhulde tabletten. |
Norway | Sitagliptin/Metformin Reddy 50 mg/850 mg filmdrasjerte tabletter. Sitagliptin/Metformin Reddy 50 mg/1,000 mg filmdrasjerte tabletter. |
Poland | Sytagliptyna + Metforminy chlorowodorek Reddy 50 mg/850 mg tabletki powlekane. Sytagliptyna + Metforminy chlorowodorek Reddy 50 mg/1,000 mg tabletki powlekane. |
Romania | Sitagliptina/Metformin Dr. Reddy’s 50 mg/850 mg comprimate filmate. Sitagliptina/Metformin Dr. Reddy’s 50 mg/1,000 mg comprimate filmate. |
Sweden | Sitagliptin/Metformin Reddy 50 mg/850 mg filmdragerade tabletter. Sitagliptin/Metformin Reddy 50 mg/1,000 mg filmdragerade tabletter. |
Slovakia | Sitagliptín/Metformin Reddy 50 mg/850 mg filmom obalené tablety. Sitagliptín/Metformin Reddy 50 mg/1,000 mg filmom obalené tablety. |
Date of the last revision of this prospectus:March 2025.
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.